Safety of Selective COX-2 Inhibitors in Aspirin/Nonsteroidal Anti-inflammatory Drug-Intolerant Patients: Comparison of Nimesulide, Meloxicam, and Rofecoxib

Journal of Asthma

Volumn 41, Issue 1, 2004, Pages 67-75

  Bavbek, Sevim ^a   Çelik, Gülfem ^a   Özer, Faruk ^a   Mungan, Dilşad ^a   Misirligil, Zeynep ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Analgesic intolerance; Asthma; Atopy; Meloxicam; Nimesulide; Rofecoxib

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2 INHIBITOR; MELOXICAM; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB;

ADULT; ANALGESIA; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTICLE; ASTHMA; ATOPY; BRONCHOSPASM; CLINICAL TRIAL; COMORBIDITY; CONTACT DERMATITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ERYTHEMA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HYPOTENSION; LARYNX EDEMA; MAJOR CLINICAL STUDY; MALE; NOSE OBSTRUCTION; PHOTOSENSITIVITY; PRURITUS; RHINITIS; RHINORRHEA; SIDE EFFECT; SNEEZING; URTICARIA; WHEEZING;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; ASTHMA; CYCLOOXYGENASE INHIBITORS; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; IMMUNOLOGIC TESTS; LACTONES; MALE; MIDDLE AGED; SINGLE-BLIND METHOD; SULFONAMIDES; SULFONES; THIAZINES; THIAZOLES; TREATMENT OUTCOME; URTICARIA;

EID: 1642278749     PISSN: 02770903     EISSN: None     Source Type: Journal    
DOI: 10.1081/JAS-120026063     Document Type: Article

References (33)

1. Sanchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F. NSAID hypersensitivity in the COX-2 inhibitor era. ACI Int 2001; 13(5):211-217.
2. Szczeklik A. The cyclooxygenase theory of aspirin-induced asthma. Eur Respir J 1990; 3:588.
3. Vigano T, Habib A, Hernandez A, Bonazzi A, Boraschi D, Lebret M, Cassina E, Maclouf J, Sala A, Falco G. Cyclooxygenase-2 and synthesis of PGE2 in human bronchial smooth-muscle cells. Am J Respir Crit Care Med 1997; 155:864.
4. Szczeklik A, Sanak M. Molecular mechanisms in aspirin-induced asthma. ACI Int 2000; 12:171.
5. 2 on this release in aspirin-sensitive asthmatics. Clin Exp Allergy 2001; 31:1615.
6. Sladek K, Dworski R, Soja J, Nizankowska E, Oates JA, Szczeklik A. Eicosanoids in bronchoalveolar lavage fluid of aspirin-intolerant patients with asthma after aspirin challenge. Am J Respir Crit Care Med 1994; 154:1608-1614.
7. Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis and management. J Allergy Clin Immunol 1999; 104:5-13.
8. Spector SL, Wangaar CH, Farr RS. Aspirin and concomitant idiosyncrasies in adult asthmatic patients. J Allergy Clin Immunol 1979; 64:500.
9. Andri L, Senna G, Betteli C, Givanni S, Scaricabarozzi I, Mezzelani P, Andri G. Tolerability of nimesulide in aspirin-sensitive patients. Ann Allergy 1994; 72:29.
10. Quaratino D, Romano A, Di Fonso M, Papa G, Perrone MR, D'Ambrosio FP, Venuti A. Tolerability of meloxicam in patients with histories of adverse reactions to nonsteroidal anti-inflammatorydrugs. Ann Allergy, Asthma, & Immun 2000; 84:513.
11. Szczeklik A, Nizankowska E, Bochenek G, Nagraba K, Mejza F, Swierczynska M. Safety of a specific COX-2 inhibitor in aspirin-induced asthma. Clin Exp Allergy 2001; 31(2)219.
12. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease and asthma. Am Rev Respir Dis 1987; 136:225.
13. Papa G, Romano A, Del Bono A, Quaratino D, Di Fonso M, Pocobelli D, Guiffreda F, Venuti A. Floctafenine: a valid alternative in patients with adverse reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy, Asthma, & Immun 1997; 78:74.
14. Çelik G, Mungan D, Bavbek S, Demirel YS, Sin B, Ediger D, Misirligil Z. The prevalence of allergic diseases and atopy in Ankara, Turkey: a two-step population-based epidemiological study. J Asthma 1999; 36:281.
15. Ispano M, Fontana A, Scibilia J, Ortolani C. Oral challenge with alternative nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol in patients intolerant to these agents. Drug 1993; 46(Suppl. 1):253.
16. Bianco S, Robuschi M, Petrigni G, Scuri M, Pieroni MG, Refini RM, Vaghi A, Sestini PS. Efficacy and tolerability of nimesulide in asthmatic patients intolerant to aspirin. Drugs 1993; 46(suppl. 1):115.
17. Vane JR. Aspirin and other anti-inflammatory drugs. Thorax 2000; 55(suppl. 2):S3-S9.
18. Bavbek S, Çelik G, Ediger D, Mungan D, Demirel YS, Msil Z. The use of nimesulide in patients with acetylsalicylic acid and nonsteroidal anti-inflammatory drug intolerance. J Asthma 1999; 36:657.
19. Asero R. Aspirin and paracetamol tolerance in patients with nimesulide-induced urticaria. Ann Allergy, Asthma, & Immun 1998; 81:237.
20. Kosnik M, Music E, Matjaz F, Suskovic S. Relative safety of meloxicam in NSAID-intolerant patients. Allergy 1998; 53:1231.
21. Ehrich EW, Dalob A, De Lepeleire I, Porras A, Wittreich J, Seibold JR, DeShepper P, Mehlisch DR, Gertz BJ. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther 1999; 65:336.
22. Yoshida S, Ishizaki Y, Onuma K, Shori T, Nakagawa H, Amayasu H. Selective cyclooxygenase inhibition in patients with aspirin-induced asthma. J Allergy Clin Immunol 2000; 106:1201-1202.
23. Gotta AW. Valdecoxib (Pharmacia). Curr Opin Investig Drugs 2002; 3(2):240-524.
24. Schwartz JI, Chan CC, Mukhopadhyaya S, McBride KJ, Jones TM, Adcock S, Moritzz C, Hedges J, Grasing K, Dobratz D, Cohen RA, Davidson MH, Bachmann KA, Gertz BJ. Cyclo-oxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans. Clin Pharmacol Ther 1999; 65:653.
25. Stevenson DD, Simon RA. Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma. J Allergy Clin Immunol 2001; 108:47-51.
26. Pacor ML, Di Lorenzo G, Biasi M, Barbagallo M, Correchor R. Safety of rofecoxib in subjects with a history of adverse cutaneous reactions to aspirin and/or non-steroidal antiinflammatory drugs. Clin Exp Allergy 2002; 32:397.
27. Stevenson DD, Simon RA. Sensitivity to aspirin and nonsteroidal antiinflammatory drugs. In: Middleton E, Reed CE, Ellis EF, Adkinson NF, Yunginger JW, Busse WW, eds. Allergy, Principles and Practice: St. Louis. Mosby-Year Book, 1993:1747-1765.
28. Stevenson DD. Challenge procedures in detection of reactions to aspirin and nonsteroidal anti-inflammatory drugs. Ann Allergy 1993; 71:417.
29. Asero R. Risk factors for acetaminophen and nimesulide intolerance in patients with NSAID-induced skin disorders. Ann Allergy, Asthma, & Immun 1999; 82:554.
30. Bochenek G, Nizankowska E, Szczeklik A. The atopy trial in hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy 1996; 51:16.
31. Sanchez-Borges M, Capriles-Hulett A. Atopy is a risk factor for nonsteroidal anti-inflammatory drug sensitivity (NSAIDs). Ann Allergy, Asthma, & Immun 2001; 84(1):101.
32. Çelik G, Mungan D, Özer F, Ediger D, Bavbek S, Sin B, Demirel YS, Misirligil Z. Clinical features and atopy profile in Turkish subjects with analgesic intolerance. J Asthma 2002; 39(2):101.
33. Pastorello EA, Zara C, Riario-Sforza GG, Pravettoni V, Incorvaria C. Atopy and intolerance of antimicrobial drugs increase the risk of reactions to acetaminophen and nimesulide in patients allergic to nonsteroidal anti-inflammatory drugs. Allergy 1998; 53:880.